TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an update.
Prescient Therapeutics has successfully completed a share placement, raising approximately $3 million from sophisticated and professional investors. This funding will support the clinical development of PTX-100, a targeted cancer therapy, and help achieve key milestones. The company has issued 11,250,000 new ordinary shares and provided a cleansing notice under the Corporations Act, ensuring compliance with regulatory requirements.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches to cancer, including targeted and cellular therapies. Their key product, PTX-100, is a first-in-class compound targeting cancer growth enzymes and has shown promising results in clinical trials. The company is also advancing its CellPryme and OmniCAR platforms to enhance cell therapy performance and enable multi-antigen targeting.
Average Trading Volume: 1,311,111
Technical Sentiment Signal: Sell
Current Market Cap: A$42.65M
Find detailed analytics on PTX stock on TipRanks’ Stock Analysis page.